- Home
- TDS vs AXSM Comparison
TDS vs AXSM Comparison
Compare TDS & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDS
- AXSM
- Stock Information
- Founded
- TDS 1968
- AXSM 2012
- Country
- TDS United States
- AXSM United States
- Employees
- TDS N/A
- AXSM N/A
- Industry
- TDS Telecommunications Equipment
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- TDS Telecommunications
- AXSM Health Care
- Exchange
- TDS Nasdaq
- AXSM Nasdaq
- Market Cap
- TDS 4.2B
- AXSM 4.8B
- IPO Year
- TDS N/A
- AXSM 2015
- Fundamental
- Price
- TDS $36.48
- AXSM $104.46
- Analyst Decision
- TDS Buy
- AXSM Strong Buy
- Analyst Count
- TDS 2
- AXSM 15
- Target Price
- TDS $53.50
- AXSM $171.00
- AVG Volume (30 Days)
- TDS 1.0M
- AXSM 912.2K
- Earning Date
- TDS 05-02-2025
- AXSM 05-05-2025
- Dividend Yield
- TDS 0.44%
- AXSM N/A
- EPS Growth
- TDS N/A
- AXSM N/A
- EPS
- TDS N/A
- AXSM N/A
- Revenue
- TDS $4,964,000,000.00
- AXSM $385,693,000.00
- Revenue This Year
- TDS N/A
- AXSM $63.85
- Revenue Next Year
- TDS $0.39
- AXSM $63.93
- P/E Ratio
- TDS N/A
- AXSM N/A
- Revenue Growth
- TDS N/A
- AXSM 42.53
- 52 Week Low
- TDS $14.04
- AXSM $64.11
- 52 Week High
- TDS $41.21
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- TDS 49.87
- AXSM 41.94
- Support Level
- TDS $35.78
- AXSM $86.99
- Resistance Level
- TDS $37.24
- AXSM $103.75
- Average True Range (ATR)
- TDS 1.78
- AXSM 5.84
- MACD
- TDS -0.10
- AXSM -0.01
- Stochastic Oscillator
- TDS 52.16
- AXSM 56.74
About TDS Telephone and Data Systems Inc.
Telephone and Data Systems Inc is a diversified telecommunications operator that provides mobile, telephone, and broadband services. The company's segments include UScellular Wireless, UScellular Towers, and TDS Telecom. It generates maximum revenue from the UScellular Wireless segment.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.